Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Array Biopharma, Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (202)	11/9/2012 6:23:49 PM
From: mcbio	1 Recommendation Read Replies (2) \| Respond to of 321

Very unhappy with the offering (namely the price) but holding for key data in 1H13 on 614 and 520. Posted notes on the NVS R&D Day at: siliconinvestor.com .

To: scaram(o)uche who wrote (202)	10/21/2013 9:55:44 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 321

>> Next, we might watch for a telegraphed combo, 162 and LEE011 (CDK4/6 inhibitor) << Ms. Church is out tweeting for ASH, and she says.... Sally Church ?@MaverickNY 15h LEE011 + BYL719 leads to tumour regression in PIK3CA mut breast cancer models #targets13 @AdamsLisa Sally Church ?@MaverickNY 15h LEE011 will also be combined with MEK162 in NRAS mut melanomas and with LGX818 to prevent emergence of resistance #targets13 v interesting Sally Church ?@MaverickNY 15h Whoa, IC50 for NVS new CDK4/6 inhibitor LEE011 are very low! Read <0.05. Being evaluated in pediatric tumours #targets13